The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index; 13 of the 14 sources its claims cite were checked for support.
Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer
Open accessAbstract
Tamoxifen (TAM) resistance remains a significant challenge in treating estrogen receptor (ER)-positive breast cancer. Overexpression of epidermal growth factor receptor (EGFR), variations in TAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer. The lack of specific drug distribution to tumors further complicates the treatment of TAM-resistant breast cancer. Simultaneously addressing these four factors—EGFR overexpression, TAM metabolic variations, P-gp-mediated drug efflux, and poor tumor-specific delivery—can significantly enhance the treatment of TAM-resistant breast cancer. This study aimed to design a multifunctional and dual-targeting polymeric prodrug nanomicelle platform. The platform was self-assembled using the amphipathic precursor drug material [hyaluronic acid (HA)-4-hydroxytamoxifen (4-OH-TAM) ester (esterified by HA and 4-OH-TAM)] and D-α-tocopheryl polyethylene glycol succinate (TPGS), loaded with dasatinib (DAS). The nanosystem could target breast cancer mediated by HA and 4-OH-TAM, releasing DAS, 4-OH-TAM, and TPGS in tumor microenvironment. 4-OH-TAM, an active metabolite of TAM, substantially impacted TAM-resistant breast cancer by avoiding the metabolic differences in TAM. TPGS inhibited P-gp-mediated drug efflux, thereby increasing intracellular accumulation of DAS and enhancing its inhibitory effect on TAM-resistant breast cancer cells.
Overview
CoChat Summary
TL;DR
The paper reports a dual-targeting polymeric prodrug nanomicelle platform, HTT-DAS, self-assembled from HA–4-OH-TAM ester and TPGS and loaded with dasatinib, for treating tamoxifen-resistant ER-positive breast cancer. It shows pH-responsive release, CD44/ER-mediated uptake, EGFR and P-gp inhibition, and stronger in vitro and in vivo antitumor effects than free 4-OH-TAM plus DAS.
Key findings
- HTT-DAS was optimized at an HT:TPGS mass ratio of 6:1 (particle size 182.1 ± 2.1 nm; PDI 0.19 ± 0.007) and a DAS:HTT ratio of 10:1 (drug loading 7.62 ± 0.32%; encapsulation efficiency 78.1 ± 3.32%); final HTT-DAS had size 189 ± 0.02 nm, PDI 0.22 ± 0.02, and zeta potential −20.77 ± 0.85 mV.
- Drug release was pH-sensitive: within 48 h at pH 5.0, cumulative release of 4-OH-TAM and DAS reached (72.73 ± 3.99)% and (78.39 ± 3.09)%, respectively, versus only (35.98 ± 4.79)% and (45.3 ± 1.66)% at pH 7.4; hemolysis was <5% at 10–320 µg/mL.
- Cellular uptake was time-dependent and dual-targeted: HTT-C6 fluorescence was stronger than TPGS-C6 and was reduced by preincubation with free HA and 4-OH-TAM; uptake was stronger in ER-positive MCF-7/TAM cells than in ER-negative MDA-MB-231 cells.
- HTT-DAS induced an apoptosis rate of (30.73 ± 3.31)% in MCF-7/TAM cells; in vivo, tumor volume was reduced to 142 mm³, and tumor weight was 0.13 ± 0.08 g, 78.3% lower than the 4-OH-TAM + DAS group (0.60 ± 0.11 g) and 87.1% lower than the control group (1.01 ± 0.27 g), with no significant body-weight loss.
- Western blotting showed DAS, DAS + 4-OH-TAM, and HTT-DAS reduced EGFR expression, but only HTT-DAS reduced P-gp expression in MCF-7/TAM cells; combination index values >1.15 indicated synergy for HTT-DAS at 24 h and 48 h, whereas free DAS + 4-OH-TAM was synergistic only at 48 h.
Methods
- HTT-DAS was prepared by film dispersion from HA–4-OH-TAM ester (HT), TPGS, and DAS; characterization included DLS, TEM, zeta potential, HPLC for drug loading/encapsulation, stability in PBS and 10% FBS, pH-dependent size/PDI, dialysis release at pH 7.4, 6.0, and 5.0, and hemolysis testing.
- In vitro studies used MCF-7/TAM (TAM-resistant, ER-positive) and MDA-MB-231 (ER-negative) cells; assays included coumarin-6 uptake by CLSM, MTT cytotoxicity, calcein-AM/PI staining, Annexin V-FITC/PI apoptosis flow cytometry, and Western blotting for EGFR and P-gp.
- In vivo studies used female BALB/c nude mice bearing MCF-7/TAM xenografts; biodistribution was assessed with Cy5/HTT-Cy5 by IVIS, and efficacy was tested with PBS, free 4-OH-TAM + DAS, or HTT-DAS (n = 5 per group) over 11 days, followed by tumor/organ H&E, EGFR immunohistochemistry, and serum biochemistry; statistics used mean ± SD with one-way ANOVA and nonparametric tests in SPSS.
Limitations
- The paper does not include a dedicated limitations section; it states that the mechanism by which TPGS together with DAS or 4-OH-TAM inhibits P-gp “requires further validation.”
- Evident from the text: in vitro mechanism and efficacy were mainly tested in one TAM-resistant ER-positive cell line (MCF-7/TAM) plus one ER-negative line (MDA-MB-231), so broader applicability across resistant breast cancer models is not established.
- Evident from the text: the in vivo efficacy study used small groups (n = 5), an 11-day treatment period, and no survival or long-term toxicity endpoints; clinical translation and comparison against TAM itself or additional controls were not reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
6 Valid · 2 Not valid · 0 Not checked · 92 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Overexpression of epidermal growth factor receptor (EGFR), variations in TAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer.”
- Also stated in: § Introduction · boosted
“Studies have demonstrated a significant increase in P-gp expression in TAM-resistant breast cancer cells19,20.”
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [19] Keller, D. N., Medwid, S. J., Ross, C. D., Wigle, T. J. & Kim, R. B. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Pharmacogenet. Genom.. 33, 10–18 (2023). source
- Disputedcites [20] Bakadlag, R., Limniatis, G., Georges, G. & Georges, E. The anti-estrogen receptor drug, tamoxifen, is selectively Lethal to P-glycoprotein-expressing Multidrug resistant tumor cells. BMC Cancer. 23, 24 (2023). sourceExperimental — accuracy not yet measured
The Discussion says the opposite of the attributed claim: P-gp-expressing drug-resistant cells are selectively sensitive to tamoxifen, and cells can escape that sensitivity by down-regulating P-gp. The paper links increased P-gp to resistance to other anticancer drugs, not to tamoxifen resistance. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Overexpression of epidermal growth factor receptor (EGFR), variations in TAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer.”
- Also stated in: § Introduction · plain
“The activation of EGFR can make ER-positive breast cancer cells resistant to endocrine therapy drugs such as TAM11,12.”
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Abstract
What the sources say
- Partly supportedcites [11] Takeda, T. et al. EGFR inhibition reverses epithelial–mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. Oncol. Rep. 47, 109 (2022). sourceExperimental — accuracy not yet measured
The section on EGFR inhibition reports higher EGFR expression in tamoxifen-resistant MCF-7/TR cells than in MCF-7 cells, and the Discussion reports that an EGFR inhibitor decreased tamoxifen resistance. These findings support a role for EGFR, but the paper does not establish that EGFR overexpression causes the development of resistance. (LLM, conf=0.83)
- Partly supportedcites [12] Siatis, K. E. et al. Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway. Am. J. Physiol.-Cell Physiol. 325, C708–C720 (2023). sourceExperimental — accuracy not yet measured
The Results report increased EGFR expression and signaling in tamoxifen-resistant MCF-7 cells, and the Discussion says resistance development was accompanied by activation of EGFR/HER2 pathways. These findings support an association, but do not establish that EGFR overexpression contributes to the development of tamoxifen resistance; the Discussion's explicit example of overexpression causing resistance concerns fulvestrant, not tamoxifen. No page numbers were provided in our copy. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Tamoxifen (TAM) resistance remains a significant challenge in treating estrogen receptor (ER)-positive breast cancer.”
- Also stated in: § Introduction · plain
“However, acquired resistance to this treatment remains a major challenge8,9.”
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Abstract
What the sources say
- Supportedcites [8] Xu, Z. et al. RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer. Redox Biol. 68, 102952 (2023). source
The Introduction identifies tamoxifen as a treatment for ER-positive breast cancer and says patients can develop resistance. The Discussion describes tamoxifen resistance as an obstacle to treating advanced breast cancer, supporting the citing sentence's broad characterization. (LLM, conf=0.94)
- Supportedcites [9] Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell. 37, 496–513 (2020). source
The Introduction describes endocrine resistance as a persistent problem in ER-positive breast cancer and specifically notes factors that reduce tamoxifen’s efficacy. The 'Aberrant co-factor activity' section describes how ER-positive breast cancer cells evade tamoxifen treatment. Together, these passages support the broad claim that tamoxifen resistance is a significant treatment challenge. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Overexpression of epidermal growth factor receptor (EGFR), variations in TAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer.”
- Also stated in: § Introduction · plain
“One of the reasons for the suboptimal efficacy of TAM in breast cancer treatment is the variability in its metabolic conversion, leading to insufficient levels of active components21.”
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Abstract
What the sources say
- Could not verifycites [21] Zlotos, D. P., Kronenberger, T. & Laufer, S. A. Anticancer drug conjugates incorporating estrogen receptor ligands. Pharmaceutics 15, 67 (2022). sourceExperimental — accuracy not yet measured
Section 2, “Hybrid Ligands Incorporating Tamoxifen” (page not provided), says chronic tamoxifen use can induce resistance and separately describes its metabolism into more potent antiestrogens. Neither that section nor the searched passages links variations in tamoxifen metabolism to the development of resistance. (LLM, conf=0.73)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“A key advantage of this system lies in the adoption of 4-OH-TAM, the active metabolite of TAM.”
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Conclusions
What the sources say
- Supportedcites [22] Khan, S. A. et al. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial. JAMA Surg. 158, 1265 (2023). source
The Plasma and Tissue Concentrations of Tamoxifen and Its Metabolites section explicitly identifies 4-hydroxytamoxifen as an active metabolite of tamoxifen. The paper also identifies endoxifen as another active metabolite; the claim does not say 4-hydroxytamoxifen is the only one. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
68 more claims · 2 with their cited sources checked
Create a free account to see all 100 claims and every source verdict.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Results and discussion > Antitumor effect of HTT-DAS nanoparticles in vivo
“A comparison of Figs. 3D and 4G reveals that HTT@DAS induced a more than 3- to 4 fold reduction in tumor volume, whereas apoptosis increased by less than 2 fold.”
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Results and discussion > Biodistribution
“(G) Quantitative analysis of tumor mass after treatments (n = 5, *P < 0.05, **P < 0.01, ***P < 0.001).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Results and discussion > In vitro pharmacodynamic evaluation of HTT-DAS
“| 30 | 18 | 0.77 | 1.3 | 1.51 | 1.76 | | 40 | 24 | 1.09 | 1.15 | 1.46 | 1.48 |”
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Materials and methods > In vitro cytotoxicity assays.
“DAS (10, 20, 50, 100, 200 µM)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Results and discussion > Antitumor effect of HTT-DAS nanoparticles in vivo
“Immunohistochemical staining for EGFR was conducted to verify the target inhibition efficacy of HTT-DAS (Fig. 5A).”
§ Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer > Results and discussion > Antitumor effect of HTT-DAS nanoparticles in vivo
“(A) H&E and EGFR immunofluorescence staining of tumor tissues after treatments.”
Citations
Cites
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Global challenges and policy solutions in breast cancer control
Trapani, D., Ginsburg, O., Fadelu, T., Lin, N. U., Hassett, M., Ilbawi, A. M., Anderson, B. O., & Curigliano, G. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102339 · Cited by 316
Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21739 · Cited by 270 · cited 1×
“P-glycoprotein (P-gp) is a typical membrane-associated pump that actively transports drugs out of cells 15 .”
The membrane receptor CD44: novel insights into metabolism
Weng, X., Maxwell-Warburton, S., Hasib, A., Ma, L., & Kang, L. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.02.002 · Cited by 254 · cited 1×
“In this system, HA and 4-OH-TAM mediated the nanomicelle targeting and enrichment in TAM-resistant breast cancer by the overexpression of ER and cluster of differentiation (CD44) receptors 28,29 .”
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253 · cited 1×
“The overexpression of P-gp in resistant cells is a self-protective mechanism of cancer cells 16–18 .”
Therapeutic resistance to anti-oestrogen therapy in breast cancer
Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00604-3 · Cited by 176
Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer
Yao, J., Deng, K., Huang, J., Zeng, R., & Zuo, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.592912 · Cited by 167 · cited 1×
“However, a reduction or absence of cytochrome P450 2D6 (CYP2D6) enzyme activity can lead to abnormal metabolism of TAM, resulting in poor therapeutic effect and pharmacological resistance 24–27 .”
Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer
Halder, J., Pradhan, D., Kar, B., Ghosh, G., & Rath, G. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102494 · Cited by 124
RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer
Xu, Z., Wang, X., Sun, W., Xu, F., Kou, H., Hu, W., Zhang, Y., Jiang, Q., Tang, J., & Xu, Y. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102952 · Cited by 76
Self-citationClinical implication of low estrogen receptor (ER-low) expression in breast cancer
Reinert, T., Cascelli, F. G. D. A., de Resende, C. A. A., Gonçalves, A. C., Godo, V. S. P., & Barrios, C. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1015388 · Cited by 46
Research works printed but not linked: 1
- Zhang, H. et al. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp). Med. Res. Rev. 41, 525–555 (2021). · DOI · Paper page
Metadata
- Authors
- Ji, Q.-L., Zeng, Y., Zhou, H., Wang, Q.-B., Zhou, R.-Y., Zhang, J.-J., & Wang, X.
- Affiliations
- Bengbu Medical College (CN)
- Corresponding author
- Zhang, Jing-jing
- Wang, Xiu
- ORCID
- Zhang, Jing-jing
- Venue
- Scientific reports
- Published
- 2026-04-26
- Volume
- 16
- Issue
- 1
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC13284359
- OpenAlex
- W7155683242
- Cited by
- 1
- References
- 31
- Citations by year
- 2026: 1
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 57 d)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- tamoxifen resistance, estrogen receptor-positive breast cancer, hyaluronic acid, 4-hydroxytamoxifen, dasatinib, TPGS, P-glycoprotein inhibition, EGFR overexpression, pH-responsive drug release, anticancer drug delivery, tamoxifen metabolism
- MeSH terms
- Dasatinib, Animals, Breast Neoplasms, Female, Humans, Hyaluronic Acid, Micelles, Polymers, Prodrugs, Tamoxifen, Vitamin E, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Nanoparticles, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer. https://app.cochat.ai/papers/10.1038/s41598-026-49617-6
- The paper
- Ji, Q.-L., Zeng, Y., Zhou, H., Wang, Q.-B., Zhou, R.-Y., Zhang, J.-J., & Wang, X. (2026). Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer. Scientific reports. https://doi.org/10.1038/s41598-026-49617-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.